TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05930015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention only
Description: Music only (120-130 bpm) The effect was achieved by playing music selected by the researchers during originally physical education classes in school; twice a week for eight weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sports games intervention only
Description: Sports games intervention only The effect was achieved by replacing the school's originally physical education classes with sports games of the researchers' choice; twice a week for eight weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and sports games intervention
Description: Music and sports games intervention, the effect was achieved by replacing the school's physical education classes with sports games of the researchers' choice, and then by playing music of the researchers' choice during class; twice a week for eight weeks
Study: NCT04037241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T cells
Description: Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T cells
Description: Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T cells
Description: Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CEA CAR-T cells
Description: Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab paclitaxel
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/nab paclitaxel
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NLIR+FU/FA
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: systemic chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: systemic chemotherapy regimen
Study: NCT05868785

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: Parenteral nutrition will be administered starting at 8 pm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Parenteral nutrition will be administered starting at 8 am
Study: NCT04026568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine
Description: Single drug test for nerve continuity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo arm
Study: NCT05448625

Intervention type: DEVICE
Intervention: Genoss DES
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study: NCT05987748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Mixed exercise training containing strength and endurance elements carried out under supervision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Mixed exercise training containing strength and endurance elements carried out under supervision
Study: NCT05699655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
Study: NCT04899479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
Study: NCT05147675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05684640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rodatristat Ethyl
Description: Tablets, Oral, 600mg, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rodatristat Ethyl
Description: Tablets, Oral, 600mg, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, BID
Study: NCT05063903

Intervention type: OTHER
Intervention: Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition
Description: Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters

Intervention type: OTHER
Intervention: Demographic and clinical characteristics, incremental shuttle walk test, six minute walk test, hand grip strength, M. Quadriceps isometric muscle strength, body composition
Description: Demographic and clinical characteristics Age and complaints, post-operative follow-up, other problems, medications, ECHO and ECG findings, laboratory tests (complete blood count, liver and kidney function tests, brain natriuretic peptide (BNP) level)~Hand grip strength Right and left hand grip strength the highest of the three measurements~Lower extremity muscle strength Maximum isometric muscle strength of the quadriceps femoris~Body composition Body fat ratio, lean body weight and fat weight by bioelectrical impedance analysis~6 minute walk test The six minute walk test distance recorded in meters~Incremental shuttle walk test The lap number, the number of laps of the last level they can reach, and the walking/running distances recorded in meters
Study: NCT05617313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously on Day 1 of cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT103
Description: 10mg/kg taken intravenously on Day 1 of cycle.
Study: NCT05473585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low nicotine content cigarettes
Description: Investigational combusted cigarettes with very low nicotine content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal nicotine content cigarettes
Description: Investigational combusted cigarettes with normal nicotine content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study e-cigarette
Description: E-cigarette provided by study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study e-cigarette
Description: E-cigarette provided by study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study e-cigarette
Description: E-cigarette provided by study
Study: NCT04725357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Description: Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Interscalene Nerve Block
Description: Preoperatively participants will standardly receive an interscalene nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Interscalene Nerve Block
Description: Preoperatively participants will standardly receive an interscalene nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic labral repair
Description: participant will have their standard surgical procedure done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic labral repair
Description: participant will have their standard surgical procedure done
Study: NCT05424432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)
Study: NCT06220695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
Study: NCT06033729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI
Description: REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
Study: NCT04914962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glazed zirconium lithium silicate
Description: monolithic glazed crown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished zirconium lithium silicate
Description: monolithic polishedcrowns
Study: NCT06144385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 . During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes. After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
Study: NCT04742790

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Scalp electroencephalography (EEG)
Description: Resting EEG will be recorded before initiation of the combination treatment (visit 1) and 7-10 days after treatment (visit 2). Drug-induced sedation-related changes in the EEG frequency spectrum. Five minutes of resting EEG eyes-open will be recorded in a quiet room while participants are asked to focus on an image displayed on a wall. Then, they will be asked to close their eyes for an additional 2 minutes. The alpha power ratio eyes open/eyes closed will be computed (alpha attenuation coefficient; Kaida et al., 2006). Changes in this coefficient will be used as a measure of drug-induced sedation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laser-evoked potentials (LEPs)
Description: Laser-evoked potentials (LEPs) will be recorded before (visit 1) and 7-10 after (visit 2) initiating the combination treatment. Short pulses (50-100 ms) of radiant heat generated by a C02 laser stimulator will be applied to the skin of the left or right hand dorm to briefly and selectively activate heat-sensitive pain receptors. A concomitant EEG recordings will be used to measure the amplitude and latency of the elicited laser-evoked potentials. Changes in LEP amplitude (expressed as percentage of change) will be used as a measure of drug-induced effects on the state of the thermonociceptive system.
Study: NCT06033729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Bolus adminitration of propofol until a Ramsey score 2-3 was reached
Study: NCT06044363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satir group
Description: Participants in the intervention group will receive a 10-session, 3-hour/session intervention that spans over a period of five days (2 sessions/day). The intervention program will be conducted on specific weekends, with a gap of 1 to 2 weeks. The total duration of the intervention will be 30 hours.
Study: NCT05926947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum A
Description: Formulation of polyphenols from olive leaf extract, blackcurrant extract, pomegranate extract, grapefruit extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum B
Description: Formulation of polyphenols from olive leaf extract, blackcurrant extract, white kidney bean extract, chromium picolinate and Zinc bisglycinate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Micro crystalline cellulose
Study: NCT05752734

Intervention type: DRUG
Intervention: Group D
Description: Patients who received 8 mg dexamethasone before bariatric surgery will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.

Intervention type: DRUG
Intervention: Group C
Description: Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.
Study: NCT05424432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Toripalimab
Description: Toripalimab 240mg every 3 weeks for two cycles (D2,D23)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Neoadjuvant Radiotherapy
Description: 30 Gy in 12 fractions, 1 fraction per day, 5 days per week, D3-D18
Study: NCT05075798

Intervention type: OTHER
Intervention: No intervention,
Description: pure observational study
Study: NCT05816603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Soterix Mini-CT tDCS stimulator
Description: Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Soterix Mini-CT tDCS stimulator
Description: Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
Study: NCT06290284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long Peripheral Catheter
Description: PowerGlide Pro™ Midline Catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Intra-Venous Catheter
Description: Venflon™ Pro Safety Needle Protected IntraVenous Cannula
Study: NCT05314647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein
Description: daily dose of 5 mg lutein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily dose of 0 mg lutein
Study: NCT05796869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: The laughter therapy session will be administered to the application group face to face for 25-30 minutes once a week for 2 months by a researcher with a laughter therapy certificate. In the laughter therapy session, introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, maintaining the rhythm with music, turning laughter that starts like a child's play into reality and meditation practices will be carried out.
Study: NCT06282458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm
Description: Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm
Description: Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide for Chronic Weight Management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide for Chronic Weight Management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide for Chronic Weight Management
Study: NCT05335863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: Participants must consume 416 mL of ONS FontActiv® DiaBest HP / HC vanilla flavor. A maximum time of 10 min will be given to consume the entire product.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Participants must consume a 50 g glucose solution in 10 min to obtain the ares under the curve (AUC) data from glucose consumption
Study: NCT05410301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Magnetic and Electric (sBE) device
Description: Home-based Static Magnetic and Electric (sBE) device that is slept in

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Magnetic and Electric (sBE) device
Description: Home-based Static Magnetic and Electric (sBE) device that is slept in

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Chemotherapy and targeted therapy drug
Study: NCT06000449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center M
Description: Digital mental health platform. Screening and prevention activities will be provided through the Center M platform, telehealth group mindfulness sessions, and digitally delivered home practice materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Paper screening and PD handout.